Laboratory diagnosis of viral hepatitis

Donna Wolk, M. F. Jones, J. E. Rosenblatt

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Both serologic and molecular assays are useful in the diagnosis of viral hepatitis. They may detect early infections before other signs of disease appear, differentiate acute from chronic infections, and detect persistence of viremia or verify development of immunity. Molecular assays may also be used to monitor responses to antiviral therapy, and in the future, be a primary method to screen blood and organ donors (NAT). EIA serologies are used to diagnose acute HAV infections or establish immune status. Similar immunoassays are used to detect HBV infections, verify persistence of antigenemia and degree of infectivity, and indicate immunity (including the response to vaccination). HBV molecular assays can shorten the diagnostic window period, verify persistence of viremia, including monitoring response to antiviral therapy, and be useful in NAT screening of donors. Molecular assays play a major role in HCV diagnosis where serologic tests can document past or present infection but cannot differentiate one from the other. A variety of molecular tests can be used as sensitive (and early) detectors of viremia (and serve as confirmatory tests for positive serologies and as donor NAT methods), document its persistence as an indicator of chronic infection, and monitor responses to antiviral therapy. Both qualitative and quantitative molecular assays are available, and their efficient use requires familiarity with the sensitivity and dynamic ranges of each method.

Original languageEnglish (US)
Pages (from-to)1109-1126
Number of pages18
JournalInfectious Disease Clinics of North America
Volume15
Issue number4
DOIs
StatePublished - 2001

Fingerprint

Clinical Laboratory Techniques
Hepatitis
Viremia
Infection
Antiviral Agents
Serology
Immunity
Tissue Donors
Donor Selection
Serologic Tests
Blood Donors
Immunoassay
Vaccination
Therapeutics
N-acetyltalosaminuronic acid

ASJC Scopus subject areas

  • Microbiology (medical)

Cite this

Laboratory diagnosis of viral hepatitis. / Wolk, Donna; Jones, M. F.; Rosenblatt, J. E.

In: Infectious Disease Clinics of North America, Vol. 15, No. 4, 2001, p. 1109-1126.

Research output: Contribution to journalArticle

Wolk, Donna ; Jones, M. F. ; Rosenblatt, J. E. / Laboratory diagnosis of viral hepatitis. In: Infectious Disease Clinics of North America. 2001 ; Vol. 15, No. 4. pp. 1109-1126.
@article{608824c055b248ee989ebb1fd335d302,
title = "Laboratory diagnosis of viral hepatitis",
abstract = "Both serologic and molecular assays are useful in the diagnosis of viral hepatitis. They may detect early infections before other signs of disease appear, differentiate acute from chronic infections, and detect persistence of viremia or verify development of immunity. Molecular assays may also be used to monitor responses to antiviral therapy, and in the future, be a primary method to screen blood and organ donors (NAT). EIA serologies are used to diagnose acute HAV infections or establish immune status. Similar immunoassays are used to detect HBV infections, verify persistence of antigenemia and degree of infectivity, and indicate immunity (including the response to vaccination). HBV molecular assays can shorten the diagnostic window period, verify persistence of viremia, including monitoring response to antiviral therapy, and be useful in NAT screening of donors. Molecular assays play a major role in HCV diagnosis where serologic tests can document past or present infection but cannot differentiate one from the other. A variety of molecular tests can be used as sensitive (and early) detectors of viremia (and serve as confirmatory tests for positive serologies and as donor NAT methods), document its persistence as an indicator of chronic infection, and monitor responses to antiviral therapy. Both qualitative and quantitative molecular assays are available, and their efficient use requires familiarity with the sensitivity and dynamic ranges of each method.",
author = "Donna Wolk and Jones, {M. F.} and Rosenblatt, {J. E.}",
year = "2001",
doi = "10.1016/S0891-5520(05)70188-4",
language = "English (US)",
volume = "15",
pages = "1109--1126",
journal = "Infectious Disease Clinics of North America",
issn = "0891-5520",
publisher = "W.B. Saunders Ltd",
number = "4",

}

TY - JOUR

T1 - Laboratory diagnosis of viral hepatitis

AU - Wolk, Donna

AU - Jones, M. F.

AU - Rosenblatt, J. E.

PY - 2001

Y1 - 2001

N2 - Both serologic and molecular assays are useful in the diagnosis of viral hepatitis. They may detect early infections before other signs of disease appear, differentiate acute from chronic infections, and detect persistence of viremia or verify development of immunity. Molecular assays may also be used to monitor responses to antiviral therapy, and in the future, be a primary method to screen blood and organ donors (NAT). EIA serologies are used to diagnose acute HAV infections or establish immune status. Similar immunoassays are used to detect HBV infections, verify persistence of antigenemia and degree of infectivity, and indicate immunity (including the response to vaccination). HBV molecular assays can shorten the diagnostic window period, verify persistence of viremia, including monitoring response to antiviral therapy, and be useful in NAT screening of donors. Molecular assays play a major role in HCV diagnosis where serologic tests can document past or present infection but cannot differentiate one from the other. A variety of molecular tests can be used as sensitive (and early) detectors of viremia (and serve as confirmatory tests for positive serologies and as donor NAT methods), document its persistence as an indicator of chronic infection, and monitor responses to antiviral therapy. Both qualitative and quantitative molecular assays are available, and their efficient use requires familiarity with the sensitivity and dynamic ranges of each method.

AB - Both serologic and molecular assays are useful in the diagnosis of viral hepatitis. They may detect early infections before other signs of disease appear, differentiate acute from chronic infections, and detect persistence of viremia or verify development of immunity. Molecular assays may also be used to monitor responses to antiviral therapy, and in the future, be a primary method to screen blood and organ donors (NAT). EIA serologies are used to diagnose acute HAV infections or establish immune status. Similar immunoassays are used to detect HBV infections, verify persistence of antigenemia and degree of infectivity, and indicate immunity (including the response to vaccination). HBV molecular assays can shorten the diagnostic window period, verify persistence of viremia, including monitoring response to antiviral therapy, and be useful in NAT screening of donors. Molecular assays play a major role in HCV diagnosis where serologic tests can document past or present infection but cannot differentiate one from the other. A variety of molecular tests can be used as sensitive (and early) detectors of viremia (and serve as confirmatory tests for positive serologies and as donor NAT methods), document its persistence as an indicator of chronic infection, and monitor responses to antiviral therapy. Both qualitative and quantitative molecular assays are available, and their efficient use requires familiarity with the sensitivity and dynamic ranges of each method.

UR - http://www.scopus.com/inward/record.url?scp=0035216138&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035216138&partnerID=8YFLogxK

U2 - 10.1016/S0891-5520(05)70188-4

DO - 10.1016/S0891-5520(05)70188-4

M3 - Article

VL - 15

SP - 1109

EP - 1126

JO - Infectious Disease Clinics of North America

JF - Infectious Disease Clinics of North America

SN - 0891-5520

IS - 4

ER -